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Abstract
Cationic (positively charged) liposomes have been tested in various gene therapy clinical trials for
neoplastic and other diseases. They have demonstrated selectivity for tumour vascular endothelial
cells raising hopes for both antiangiogenic and antivascular therapies. They are also capable of being
selectively delivered to the lungs and liver when administered intravenously. These vesicles are
being targeted to the tumour in various parts of the body by using advanced liposomal systems such
as ligand-receptor and antibody-antigen combinations. At present, the transferrin receptor is
commonly used for cancer-targeted drug delivery systems including cationic liposomes. This review
looks at the growing utility of these vesicles for delivery of small molecule anticancer drugs.
Introduction
Modern medicine is successful in achieving disease-free
survival in a good number of cancer patients. However, in
a majority of cases, medical intervention is only successful
in prolonging the life of a patient from months to a few
years. Cancer is essentially a pathology with various
mechanisms at its disposal to avert its own destruction.
Thus, multi-modal therapy is required, with or without
surgical intervention. Novel therapies are constantly being
discovered, developed and trialled, with neoplasia target-
ing given high priority. For all forms of therapies, a com-
mon thread is the need for targeting to avoid side-effects
of drugs. In the past few years, cationic liposomes (CLs)
have been shown to be selective for tumour vascular
endothelial cells (VECs). In addition, as mentioned
below, a handful of papers highlight the ability of target-
ing these vesicles to tumours in various parts of the body
by using advanced liposome drug delivery systems
(DDSs).
Molecular therapy, is a promising strategy for the treat-
ment of human disease. However, as above-mentioned,
delivery of molecular therapeutics efficiently and specifi-
cally to the target tissue remains a significant challenge. A
great deal of research has been done to address the diffi-
culties faced by a drug molecule as it leaves its site of
administration and distributes in the body, hopefully
reaching the target site at doses sufficient to alter the
pathology, or halt disease progression. Whilst this is true
generically for all diseases amenable to drug therapy, it is
particularly so for cancer, which challenges modern med-
icine with the ability to grow at a rapid rate, actively pump
out drugs from cancer cells, and spread through the
bloodstream to reside in secondary spots in the body.
It is the process of metastasis (cancer spread), which even-
tually kills the patient in most cases. Current surgery can
quite aptly remove much of the bulk of a primary tumour
and is useful in certain types of metastectomy, such as in
the lungs of osteosarcoma patients. Radiotherapy is uti-
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lised in specific types of tumours, but chemotherapy is
very common for a variety of cancers. Regimes using mul-
tiple drugs for the one patient is more the norm than the
exception nowadays. These conventional forms of thera-
pies do have success in quite a lot of patients, but there is
still that gap in knowledge as to what causes a cancer to
initiate, become latent, then progress rapidly, and finally
spread. Such answers can only come about with increased
basic academic research. Nevertheless, one of the promis-
ing offshoots of basic research has been the emergence of
novel forms of therapies for cancer or the re-examination
of various ways to better target diseased tissue.
For cancer, regional or local administration is possible for
certain lesions such as head and neck cancer and
melanoma. For deep-seated tumours, limited targeting
has been achieved via selective delivery using upstream
intraarterial administration of microspheres [1], use of
immunoliposomes [2], and exploitation of ligand-recep-
tor interactions [3], mostly at the preclinical stage. The
ability of the above examples has been extensively dem-
onstrated in vitro with cultured cells. However, there is a
paucity of literature following up with in vivo demonstra-
tion for a majority of them.
Thus, the main hurdle is how to fulfil the targeting aspect
of these concepts when treating a tumour in an organism.
In general, only those ideas that are realised by the merg-
ing of different concepts seem to proceed and deliver
results, albeit hardly impressively. Thus, there is a real
need for better ways to deliver therapeutics to tumours in
vivo. This review looks at these issues and ways to improve
on the current situation for CLs, an entity that has
attributes placing it among one of the most promising
delivery agents for targeting small molecule therapy for
cancer. For the purposes of this review, small molecule
drugs refer to cytotoxic agents which are xenobiotic and
which are much smaller chemically than biologicals such
as protein or oligonucleotides.
Cationic liposomes
It is nearly two decades now since a cationic lipid was
seminally used to introduce plasmid DNA into cells [4].
Since then, numerous cationic liposomes (CLs, also called
cytofectins or lipofection reagents) have been synthesised
and used for delivery of nucleic acids into cells in culture,
in animals and in patients enrolled in phase I and II clin-
ical trials. In comparison to other gene delivery modes,
such as viral vectors, CLs, the most common transfection
reagent, are technically simple and quick to formulate, are
not as biologically hazardous as viral vectors, are readily
available commercially, and may be tailored for specific
applications.
After the initial surge in use of CLs for transfection of cul-
tured cells and gene transfer in animals, the realisation
that they had limitations, prompted a re-evaluation of
their design. The overriding concern was the degree of tox-
icity that CLs exhibited in cultured cells and that these
effects were at times drastically pronounced in several ani-
mal studies [5]. When low doses of CLs are employed in
vivo, transfection results are only slightly better than
naked gene delivery, thus signalling the need for adminis-
tration of higher doses, which then tend to be toxic. In
light of the fine balance between toxicity and efficacy, the
past seven years has brought about a major re-emphasis
on vehicle safety.
Recently, there has been renewed interest in cationic lipo-
somes, mainly due to their inherent yet unexplained abil-
ity to target certain features of a growing tumour mass.
These vesicles have been shown, as specific examples
below will highlight, the ability not only to target carried
agents to the tumour cells, but the suppliant vasculature
endothelial cells, thereby having great utility in anti-ang-
iogenesis and anti-vascular therapy.
The role of non-cationic helper lipids such as the neutral
dioleoylphosphatidylethanolamine (DOPE) is to facili-
tate membrane fusion and aid in the destabilisation of the
plasmalemma or endosome [6]. In addition, these sup-
porting lipids stabilise the cationic liposome suspension
as cationic lipids repel each other [7] and to counteract the
uptake-opposing effects of anionic glycosaminoglycans
noted in other carriers such as polyethyleneimine (PEI)
and dendrimers [8]. Liposomes formulated without neu-
tral lipid(s) have inferior rates of cellular uptake [9],
whilst varying rates may result from varying ratios of cati-
onic:neutral lipid used to formulate the liposomes
[10,11].
As above-mentioned, the success of cationic liposome-
mediated nucleic acid transfer is dependent on numerous
factors that may explain the inherent variability of lipofec-
tion (lipoplex-mediated transfection), particularly in vivo
[1,12]. These vehicles have been proven to be non-toxic in
a majority of investigations, including phase I and II clin-
ical trials, albeit varying degrees of toxicity still emerge
occasionally [reviewed in 13]. Some of this is due to the
carried nucleic acid, whilst others are due to the cationic
lipidic components of the vesicle, or in fact even the com-
bined effects of the lipoplexes formed.
Some of the earlier generation cationic lipids such as
DMRIE [()-N-(2-hydroxyethyl)-N, N-dimethyl-2, 3-
bis(tetradecycloxy)-1-propanaminium bromide] and DC-
Chol were tested in clinical trials [reviewed in 13], but the
resultant biological (therapeutic) effects with these vesi-
cles were at best marginal, with toxicity overshadowingCancer Cell International 2006, 6:17 http://www.cancerci.com/content/6/1/17
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any beneficial effects of transgene expression. Recent
research has pinpointed certain features of CLs that
enhance their capability for nucleic acid transport in vivo.
These may also be highly relevant to small molecule deliv-
ery and include the cationic head group and its neigh-
bouring aliphatic chain being in a 1,2-relationship on the
backbone, an ether bond for bridging the aliphatic chains
to the backbone, and paired oleyl chains acting as the
hydrophobic tether [14]. Ester bonds within the linker
region are believed to be better due to their degradation in
cells, thereby reducing cytotoxicity [15]. Biodegradation is
currently a key feature sought in DDSs.
In any case, these features, whilst not determining better
transfection capacity in cell culture, facilitate better
nucleic acid delivery in vivo. Thus, in vitro and cell culture
results have to be treated with caution and cannot neces-
sarily be used to extrapolate the genuine potential of a
nucleic acid carrier in vivo. Other factors such as particle
diameter and route of administration become more
important when these vesicles are introduced in vivo [16].
Finally, what may be a good lipofection reagent for one
application, may not necessarily prove to be ideal for
another. A substantial quantity of empirical research to
determine the optimal conditions for in vitro and in vivo
transfection with CLs is usually required.
Evidence for selective delivery of CLs to tumour 
VECs
It is now a well-known fact that CLs target quite selec-
tively, the vasculature of tumours, a phenomenon not
noted with anionic (negatively charged) or electroneutral
(zero charge potential) liposomes [17]. Campbell and
colleagues [18] found that CLs, sterically stabilised with
the addition of 5% molar PEG, accumulated more in such
vessels when CLs were used as opposed to neutral charged
liposomes. Inclusion of PEGylated lipids in the vesicles
has the added advantage of reducing aggregate formation
[19], thus increasing both yield and injectability of com-
plexes. Unmodified lipoplexes have a relatively short cir-
culation half-life of less than 5 minutes [18]. Furthermore,
when the percentage of cationic lipid is increased from 10
to 50% molar, the accumulation in tumour VECs
increases by 100%.
The inclusion of PEGylated lipids delay liposome clear-
ance from blood, but not at the expense of interaction and
uptake by tumour VECs [18]. It is a well-known fact that
the inclusion of PEGylated lipids on the liposome surface
significantly increases circulation half-life in vivo. In con-
trast, no change in interstitial accumulation could be
detected. This selective delivery to tumour VECs was
noted in two human tumour types (LS174T and MCAIV)
and at two locations (cranial window and dorsal skin fold
chamber). Distribution of vesicles in tumour vessels was
heterogeneous, and this may have some bearing on
whether this technology is powerful enough to destroy
enough tumour VECs to induce tumour regression. Inter-
estingly, a 50% molar charge on the liposomes signifi-
cantly increased accumulation in the lungs of mice 24 h
post-injection. Thus, for pulmonary metastasis, this could
be of substantial benefit.
Based on several lines of evidence, it is believed that mam-
malian cells interact with and internalise cationic macro-
molecules by endocytosis [20], and that this interaction is
at least partially mediated by proteoglycans [21]. Further-
more, in the case of mosaic tumour vessels (vessels com-
prised of both VECs and tumour cells), the tumour cells
are in direct contact with cationised macromolecules,
including CLs, and uptake should occur in both VECs and
neoplastic cells [22]. Thus, in theory at least, cargo deliv-
ered by CLs should selectively be delivered to the support-
ing neovasculature and directly to tumour cells. Mitotic
index is believed to play a major role in the uptake of
delivered agents selectively to tumour cells [23].
Earlier on, Thurston and coworkers [24] demonstrated
that in the RIP-Tag2 and the K14-HPV16 tumour models,
the quantity of liposomes accumulating in tumour vessels
were up to 33-fold than that in corresponding vessels in
non-tumour-bearing mice. Of the CLs inside tumour
VECs, 89% were in multivesicular bodies, 10% in small
vesicles, and ~1% in complex structures composed of
multiple interconnecting vesicles, all probably at various
stages of the vesiculo-vacuolar organelle (VVO) system.
Notable was the observation that within 20 minutes of
intravenous injection, liposomes appeared on the luminal
surface of angiogenic VECs or in vesicular structures
within these cells [24]. Furthermore, 51% of the CLs accu-
mulating on the tumour VEC surface were associated with
fenestrae, although fenestrae constituted a mere 4% of the
luminal VEC surface. This could be attributed to the posi-
tive charge on the vesicle surface, since cationic ferritin,
but not native ferritin, exhibits ready binding to fenestrae,
suggesting the presence of anionic moieties on fenestral
diaphragms [25]. Such interaction may take place at the
coated pit present on VECs, since these sites are known to
bind cationic molecules, albeit guiding them down the
endosomal pathway to destruction [26]. Thurston and
colleagues [24] put forward several lines of evidence indi-
cating that extravasation was due to trans-VEC transport
rather than via leakage through the basement membranes
of tumour endothelium.
Selective delivery of small molecule drugs to 
tumour and its vasculature
The vascular network is naturally highly accessible to
intravascularly-administered therapeutic agents. Regard-Cancer Cell International 2006, 6:17 http://www.cancerci.com/content/6/1/17
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less of the route of administration, once the agent gains
access to the circulatory system, it has the potential to tar-
get actively proliferating vessels, such as those in a
tumour. The vasculature of the tumour also occupies a rel-
atively small area in comparison to the tumour intersti-
tium, thus the doses of antiangiogenic agents to be
delivered in vivo should theoretically be much less than
what needs to be administered for general anticancer
chemotherapeutics.
Conventional cytotoxic agents that recently have been
found to be antiangiogenic, such as vinblastine and pacl-
itaxel, would need to be injected in much smaller doses,
albeit maybe more frequently in keeping with metro-
nomic dosing schedules [27]. Regardless of efficacy, the
effects of such targeted therapy has to be monitored in
models also looking at whether physiological angiogen-
esis, such as that occurring in the menstrual cycle and
wound healing, is perturbed as well.
CLs are capable of causing an antivascular effect with cyto-
toxic agents. For instance, Kunstfeld and coworkers [28]
demonstrated that paclitaxel encapsulated in CLs dimin-
ishes tumour angiogenesis and inhibits orthotopic
melanoma growth in SCID mice. In contrast, paclitaxel
administered in its normal Cremophor EL medium, while
showing an inhibitory effect in cell culture, was unable to
significantly decrease angiogenesis and tumour growth in
vivo. Kunstfeld and colleagues [28] speculate further that
factors governing constitutive mitosis, such as that in nor-
mal physiological processes, are different from that induc-
ing division in angiogenic vessels.
Strieth and colleagues [29] used the dorsal skinfold cham-
ber method, A-Mel-3 melanomas and intravenous paclit-
axel to demonstrate that tumour growth was significantly
inhibited after treatment with paclitaxel within CLs com-
pared to the treatment with non-liposomal paclitaxel.
Encapsulated paclitaxel caused a decrease of functional
tumour vessel density and a constriction of vessel diame-
ters. This resulted in a significantly reduced blood flow in
vessel segments and a reduced microcirculatory perfusion
index in these animals. The degree of apoptosis in the
vicinity of the vessels was significantly increased when
animals were administered liposomal paclitaxel.
Schmitt-Sody and colleagues [30], in A-Mel-3 tumours in
dorsal skinfold preparations, demonstrated that vascular
targeting of paclitaxel-containing CLs was achieved after
encapsulation. Tumour growth was significantly inhibited
when compared to control groups. In addition, the
appearance of regional lymph node metastases was signif-
icantly delayed by treatment with paclitaxel encapsulated
into CLs in comparison with all other groups. Krasnici
and coworkers [31] utilised A-Mel-3 growing in the dorsal
skinfold to demonstrate that after intravenous application
of anionic and neutral liposomes, there was no specific
targeting to tumour tissue. In contrast, CLs exhibited a sig-
nificantly enhanced accumulation in tumour tissue and
tumour vasculature up to 3-fold compared to surrounding
tissue within 20 minutes post-administration.
Thus, there is ample evidence that CLs have the inherent
potential for selective delivery to tumour VECs. Surpris-
ingly, not much more work has been done to exploit this
phenomenon. However, the results of studies [28-30]
have led to the phase I trial of the first such complex
termed MBT-0206, which is comprised of Taxol® and the
lipidic vehicle called EndoTAG™. Nevertheless, CLs have
also been shown to target other tissues in the body, albeit
with substantial modifications to their overall structure as
highlighted in the examples below. As shown in Figure 1,
further modifications to CLs may indeed increase their
cancer targeting ability. Such modifications include inclu-
sion of pegylated lipids for enhanced circulation. Tumour
cell specific ligands or antibodies may be included on the
liposome coat to allow specificity of drug delivery. Finally,
because these liposomes can be formulated with bilayers,
they may ferry both hydrophobic drugs (between the lipid
bilayer sandwich) and hydrophilic drugs (within the
aqueous space in the core of the vesicles). In addition,
their positive charge-coated surface may also carry anionic
drugs purely by electrostatic attraction.
Targeted liposomal delivery of transgenes to 
non-endothelium tissues
CLs have been used to selectively deliver their genetic pay-
load to tissues other than the endothelium. As the specific
examples below show, most work has been carried out
with either ligand-receptor or antibody-antigen recogni-
tion. The increasing number of papers detailing in vivo
success with these entities especially for gene transfer
attest to the latent potential of this technology for target-
ing small molecular cytotoxics as well. A common system
used is that of the transferrin (Tf) receptor (TfR) for bind-
ing and cell entry, as these TfRs are over-expressed by a
variety of tumour cells and are widely being investigated
for tumour-targeted drug delivery. Many neoplastic cells
overexpress the transferrin receptor to increase their iron
uptake.
The use of the Tf ligand to target a CL delivery system
resulted in a significant increase in the transfection effi-
ciency of the complex [32]. Delivery of wild-type (wt) p53
to a radiation-resistant squamous cell carcinoma of the
head and neck (SCCHN) cell line via this ligand-targeted,
liposome complex was also able to revert the radiation
resistant phenotype of these cells in vitro. The Tf-targeted
CL-DNA complex showed high gene transfer efficiency
and efficacy with human head and neck cancer in vitro andCancer Cell International 2006, 6:17 http://www.cancerci.com/content/6/1/17
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in vivo [33]. Intravenous liposome administration of wt
p53 markedly sensitized established SCCHN nude mouse
xenograft tumors to radiotherapy, and led to complete
tumour regression. It is not hard to imagine that a similar
ligand-targeted approach can be highly efficacious for
small molecule therapy.
Xu and colleagues [34] then went on to describe a novel
cationic immunolipoplex system that showed high in vivo
gene transfer efficiency and anti- tumour efficacy when
used for systemic p53 gene therapy of cancer. The novel
cationic immunolipoplex incorporating a biosyntheti-
cally lipid-tagged, anti-transferrin receptor single-chain
antibody (TfRscFv) targeted tumour cells both in vitro and
in vivo. A human breast cancer metastasis model was
employed to demonstrate that the TfRscFv-targeting cati-
onic immunolipoplex enhanced tumour cell binding, and
improved targeted gene delivery and transfection efficien-
cies. The combination of the p53 gene delivered by the
systemic administration of the TfRscFv-immunolipoplex
and docetaxel resulted in significantly improved efficacy
with prolonged survival.
Xu and coworkers [35] explored the structure, size, forma-
tion process, and structure-function relationships of a Tf-
lipoplex. They observed that Tf-lipoplex had a highly
compact structure, with a relatively uniform size of 50–90
nm, resembling a virus particle with a dense core envel-
oped by a membrane coated with Tf molecules spiking the
surface. The Tf-lipoplex showed enhanced stability,
improved in vivo gene transfer efficiency, and long-term
efficacy for systemic p53 gene therapy of human prostate
cancer when used in combination with conventional radi-
otherapy. A multistep self-assembly process and a Tf-facil-
An ideal cationic liposome Figure 1
An ideal cationic liposome. A vesicle capable of targeting tumour vessels and tumour cells in vivo and that consists of two com-
partments – hydrophilic core (blue) and hydrophobic sandwiched bilayer (red).
cationic lipid
neutral lipid
ligand
antibody
pegylated lipidCancer Cell International 2006, 6:17 http://www.cancerci.com/content/6/1/17
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itated DNA co-condensation model that may provide an
explanation for the resultant small size and effectiveness
of the nanostructural Tf-lipoplex system was proposed by
the authors. For small molecules, reducing particle size
will be easier since these chemicals structures are signifi-
cantly smaller and lack even secondary structure in com-
parison to long DNA or RNA strands.
TfRscFv has a number of advantages over the transferrin
(Tf) molecule itself, including the fact that scFv has a
much smaller size than Tf producing a smaller immunol-
ipoplex giving better penetration into solid tumors.
Unlike Tf, scFv is a recombinant protein, not a blood
product, and thus large scale production and strict quality
control of the recombinant scFv, as well as scFv-immuno-
lipoplex, are possible. The sensitization of tumours to
chemotherapy by this tumour-targeted and efficient gene
transfer method could lower the effective dose of the drug,
correspondingly lessening the severe side effects, while
decreasing the possibility of recurrence. Moreover, this
approach is applicable to both primary and recurrent
tumours, and more significantly, metastatic disease. How-
ever, one area of improvement is to increase the low yield
of this lipid-tagged scFv to facilitate further development
and studies.
Yu and colleagues [36] developed a sterically stabilized
immunolipoplex (TsPLP), containing an antitransferrin
receptor single-chain antibody fragment (TfRscFv)-PEG
molecule, to specifically and efficiently deliver a therapeu-
tic gene to tumour cells. The lipoplex was formed first and
then sequentially conjugated with PEG and TfRscFv. The
complex prepared by this method was shown to be supe-
rior in ability to target genes to tumour cells than when
prepared by a common precoating strategy, in which DNA
is mixed with TfRscFv-PEG conjugated liposome. Using
the prostate cancer cell line DU145, it was found that the
level of exogenous gene expression in the TSPLP trans-
fected tumours was 2-fold higher than non-PEGylated
liposomes and transgene expression did not decrease over
time. More importantly, high exogenous gene expression
in tumour, but low expression in liver, was observed after
an intravenous delivery of TsPLP.
The above technology has been shown to be efficient for
targeting plasmid, antisense and siRNA strands to
tumours in vivo [37]. Thus, since targeting is to a naturally
present receptor system on cells that is overrepresented in
cancer cells, in essence, targeting of any biomolecule that
is able to be linked to the ligand of the receptor or an anti-
body fragment to it should theoretically facilitate delivery
to tumours selectively in vivo. Use of CLs with PEGylated
lipids and TfR-targeted moieties not only should target
tumour tissue, but enhance circulation time and also be
capable of selectively destroying tumour VECs. This dual-
pronged effect makes this mechanism a highly attractive
one and warrants further development.
Foreseeable problems for small molecule 
delivery using CLs
While cationic agents may be effective at mediating DNA
uptake in cells in culture or when delivered locally in vivo,
their use as systemic delivery agents is limited due to the
size and high superficial charge of the lipid complexes.
Thus, controlled release systems with minimal charge and
optimum particle diameter are needed. This entails a lot
of empirical research at the pre-in vivo stage. For the
former, optimisation of positive-to-negative charge ratio
is important, while for the latter, sizing variations using
common techniques such as extrusion, freeze-thaw, and
sonication need to be empirically determined.
For lipoplexes, intravenous delivery of oligonucleotides
complexed with DC-Chol/DOPE in mice leads to a rapid
deposition in the capillary beds of the lung followed by
release into the plasma and ultimate clearance into the
spleen and liver [38]. This may not be the case for small
molecule drugs as they theoretically should not form such
complexes due to their small chemical structure and sig-
nificantly less charge per molecule. Oligonucleotides,
being highly anionic, are notorious for forming bridging
bonds between complexes, forming complexes that even
becoming macroscopic and sometimes precipitating out
of solution [39].
On the other hand, some complexation may prove to be
beneficial. The natural tendency for lung and liver uptake
via intravenous administration may be exploited for erad-
ication of pulmonary and hepatic metastases. Such an
approach has been taken by several groups with varying
degrees of success for pulmonary [40,41] and hepatic
[42,43] metastases gene delivery. The inclusion of addi-
tional molecules into liposomes that could cause aggrega-
tion, such as oligonucleotides, may abet such delivery to
metastatic growths. However, it would be important to
predetermine whether such additions do not interfere
with drug-target interactions at the diseased site. The chal-
lenge, once again, is to limit distribution of therapeutics
to other healthy tissues.
Future directions
The fact that CLs are able to selectively deliver their carried
load to certain tissues such as tumour endothelium, lungs
and liver, make them quite attractive commodities for
cancer therapy. However, on the downside, these vesicles
tend to aggregate and have the potential to form microem-
boli in vivo. Tissue ischaemia may be problematic, but in
the case of tumours, shutting down of the blood supply is
in fact very much a goal. In any case, these microemboli
may then serve as depots from which a sustained releaseCancer Cell International 2006, 6:17 http://www.cancerci.com/content/6/1/17
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of lipoplexes from within the tumour microvascular bed
may occur. Such controlled release delivery is a highly
desired feature in any therapeutic DDS and has been
shown to work with microspheres [1,44], even clinically
[45,46]. This system of selective delivery is particularly
useful for osteosarcoma and renal cancers [47], where the
vasculature is well established.
New techniques such as those used for preparing coated
CLs [48], have shown promise in vivo for targeting to
hepatic VECs when liposomal surfaces were embedded
with human serum albumin [49]. Docking of liposomes
on to microspheres has also been shown to enhance
tumour:normal gene delivery in vivo when administered
upstream of the tumour intraarterially [50]. Furthermore,
it has recently been shown that coating adenoviral gene
vectors with CLs shields them from immunorecognition
of these novel entities, albeit at the expense of a higher
rate of cytotoxicity [51].
Stabilised lipid particles [52], containing a PEGylated
lipid for extended circulation of what is essentially a CL,
has recently been shown to bypass so-called 'first pass'
organs, including the lung, and elicit levels of gene expres-
sion in distal tumour tissue 100- to 1000-fold greater than
that observed in normal tissues [53]. These vesicles load
the plasmids using the positive charge of the cationic lip-
idic constituent of the vesicle, before the charge is neutral-
ised so that in vivo both cytotoxicity and opsonisation may
be reduced. One criticism of such a modification may be
whether the inherent anticancer properties of the cationic
lipids [13] are reduced when the charge of these lipids are
masked.
For most types of liposomes, the field has had to evolve
and use a variety of methods incorporating the positive
aspects of different vesicles to create better new generation
DDSs (Figure 1) capable of ferrying both gene vectors as
well as small molecule drugs such as paclitaxel. This has
been the case at least for the past decade [54] and it is
apparent that such a challenge will take significant time
and substantial resources before significant improve-
ments over the existing liposomes take place. Amongst all
the variety of liposomes, CLs have been one class that
have been developed, tested and modified both rapidly
and intensively.
In fact, one may argue that CLs have given liposomolo-
gists a much needed boost in their efforts to enhance drug
pharmacokinetics. These vesicles were taken into the
clinic within a decade of their discovery, an amazing feat
per se. Clinical evaluation was preceded by numerous
studies looking at the safety, pharmacokinetics and phar-
macodynamics in animals. Even when faced with mount-
ing criticism, CLs have persisted and as yet have to be
replaced by other types of liposomes or other types of
gene delivery mechanisms such as viral vectors.
Further fine-tuning is definitely required, but with the
quantity and quality of research being carried out, the task
does not seem insurmountable anymore. The search for
elements for fine-tuning of CLs should not be limited to
lipidic or non-lipidic components, but other aspects of
drug delivery such as choosing better routes of administra-
tion. The past of focussed research in well-defined, gener-
ally mutually exclusive circles have well and truly been
replaced with research where delineations are blurred and
the central aim is to help those suffering from ailments in
the most rapid format that is possible.
Summary
Cationic liposomes, which have been around for 2 dec-
ades now, have been tested in various gene therapy clini-
cal trials for cancer and other genetic pathologies. These
class of vesicles have selectivity for tumour vascular
endothelial cells as well as being selectively delivered to
the lungs and liver when administered intravenously.
These vesicles are capable of targeting the tumour via
advanced liposomal systems such as antibody-antigen or
ligand-receptor recognition. While delivery of genes and
gene-modulating oligonucleotides are the norm for this
class of vehicles, they are increasingly being tested for con-
ventionally drug delivery as well. Fine-tuning is needed if
small molecule drug delivery with these carriers are to be
adopted for clinical testing.
Abbreviations
CL, cationic liposome, DDS, drug delivery system, Tf,
transferrin, TfR, Tf receptor, VEC, vascular endothelial cell
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